VivoSeq
Cardiovascular

Brain Ischemia

13

Pipeline Programs↗

0

Active Trials↗

10

Companies Involved↗

Brain Ischemia is an emerging landscape with 13 programs across 10 companies. The most active players are Neurim Pharmaceuticals Ltd., Kaken Pharmaceutical, Amgen. 3 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

39/100

Pipeline Velocity

0/100

Mech. Concentration

22/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

N

Neurim Pharmaceuticals Ltd.

1 program

Phase 1K

Kaken Pharmaceutical

1 program

Phase 1Amgen logo

Amgen

1 program

Phase 1N

Nobilis Therapeutics Inc.

1 program

Phase 2Roche logo

Roche

2 programs

Phase 3Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

83%

Small molecule

10 of 12 classified programs — the dominant modality here.

17%ALL OTHERSMonoclonal antibody18%Protein / enzyme18%

Small molecule leads; the ring shows all 12 classified programs, each share of the total. Modality classified for 100% of 14 pipeline programs.

Analysis

Trial Status

1

clinical trials

Completed1 · 100%

Clinical Trials

Trial Activity

Effect of Xenon and Therapeutic Hypothermia, on the Brain and on Neurological Outcome Following Brain Ischemia in Cardiac Arrest Patients
Completed·TTurku University Hospital·Phase 2·NCT00879892·110 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)